Stockreport

Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)

Synlogic, Inc.  (SYBX) 
Last synlogic, inc. earnings: 3/12 04:19 pm Check Earnings Report
PDF – Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria –– Synlogic has initiated a bridging study of a ne [Read more]